

# ROSWELL PARK COMPREHENSIVE CANCER CENTER

## CLINICAL UPDATES IN HEMATOLOGIC MALIGNANCIES

### AND RELATED SUPPORTIVE CARE

#### Program Agenda

Day 1: February 4, 2023

8:00 am–8:10 am	<b>Greetings and Introduction</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
	<b>Diffuse Large B-cell lymphoma</b> <b>Program Chair: <i>Francisco Hernandez-Ilizaliturri, MD</i></b>
8:10 am – 8:15 am	<b>Case Presentation of DLBCL</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
8:15 am – 8:40 am	<b>Clinical Practice Changes in the front-line Management of DLBCL</b> <i>Dr. Kieron Dunleavy</i> <ol style="list-style-type: none"><li>Describe how to tailor the management of DLBCL in the first line setting. Discuss how the cell origin and/or cytogenetics affect treatment decision-making?</li><li>Discuss the management of elderly patients with DLBCL.</li><li>List the novel therapeutic agents that are being developed for the front-line management of aggressive lymphoma.</li><li>What is the status of CNS prophylaxis in the management of DLBCL?</li></ol>
8:45 am – 9:10 am	<b>Clinical Practice Changes in the Management of relapsed/refractory DLBCL</b> <i>Dr. Jeremy Abramson</i> <ol style="list-style-type: none"><li>Describe how to tailor the management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) based on duration of initial response, age, molecular profiling, etc., i.e., how to make the best treatment decision.</li><li>Discuss the management of elderly patients with relapsed/refractory DLBCL.</li><li>List the novel therapeutic agents that are being developed for the management of relapsed/refractory DLBCL.</li><li>Selecting the best anti-CD19 targeted therapy for r/r DLBCL.</li></ol>
9:15 am – 9:20 am	<b>Case Presentation of MCL</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
9:20 am – 9:45 am	<b>Mantle cell lymphoma: Evolving changes in molecular characterization and treatment modalities.</b> <i>Dr. Julio Chavez</i> <ol style="list-style-type: none"><li>Discuss changes in the molecular sub-characterization of MCL and how this impacts clinical prognosis and treatment.</li><li>Review practice changes in the management of MCL in the front-line setting and relapsed/refractory setting.</li></ol>
9:45 am – 10:15	<b>Interactive Round Table</b>
10:15 am – 10:30 am	BREAK

# ROSWELL PARK COMPREHENSIVE CANCER CENTER

## CLINICAL UPDATES IN HEMATOLOGIC MALIGNANCIES

### AND RELATED SUPPORTIVE CARE

#### Program Agenda

Day 1: February 4, 2023 cont'd

<b>Cellular Therapy and Bi-specific Antibodies</b> <b>Program Chair: Marco Davila, MD</b>	
10:30 am – 10:35 am	<b>DLBCL Case Presentation</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
10:35 am – 11:00 am	<b>Cellular Therapy for Lymphoid Malignancies</b> <i>Dr. Marco Davila</i> <ol style="list-style-type: none"><li>Illustrate the history of the development of chimeric antigen receptor T-cell therapy against CD19 (CAR-T 19 therapy).</li><li>Assess who is the ideal patient for CAR-T 19 therapy in B-cell lymphoma.</li><li>Describe how effective CAR-T 19 therapy in High grade B-cell lymphoma is.</li></ol>
11:05 am – 11:30 am	<b>Beyond CD19 targeted cellular therapies for lymphoid malignancies</b> <i>Dr. Catherine Bollard</i> <ol style="list-style-type: none"><li>To better understand the technological advances in chimeric antigen receptor T-cell therapies.</li><li>Describe the use of cellular therapies for patients with virally induced lymphomas, T-cell lymphoma, or Hodgkin's disease. When to use them and who should be considered?</li><li>What is the role of allogeneic CAR T-cell or NK-cell directed therapies in hematological malignancies?</li></ol>
11:35 am – 12:00 pm	<b>Cellular Therapy for Multiple Myeloma</b> <i>Dr. Philip McCarthy</i> <ol style="list-style-type: none"><li>Identify who is the ideal patient for CART therapy in MM.</li><li>Determine how effective CART therapy in MM is.</li><li>Discuss what CART constructs are being developed in MM.</li></ol>
12:05 pm – 1:05 pm	<b>PLENARY LUNCHEON</b> <b>The past, present, and future of cellular therapy</b> <i>Dr. Renier Brentjens</i>
1:10 pm – 1:35 pm	<b>Bi-specific antibodies in hematological malignancies</b> <i>Dr. Francisco Hernandez-Ilizaliturri</i> <ol style="list-style-type: none"><li>Describe the mechanism of action of bi-specific antibodies.</li><li>Review the clinical data of bi-specific antibodies in hematological malignancies.</li><li>Describe the rational combinations with bi-specific antibodies and other targeted agents.</li><li>What is the future for bi-specific antibodies?</li></ol>
1:40 pm – 2:05 pm	<b>What are the infectious complications after CAR T cell therapy and what is the significance of CMV reactivation</b> <i>Dr. George Chen</i> <ol style="list-style-type: none"><li>Discuss the ABCs of recognizing CRS and Neurotoxicity in CART therapy patients.</li><li>Describe how to manage CRS.</li><li>Describe how to manage Neurotoxicity in CART19 therapy.</li><li>Discuss emerging opportunistic infections in CART therapy patients.</li></ol>

2:10 pm – 2:40 pm

Interactive Round Table

## ROSWELL PARK COMPREHENSIVE CANCER CENTER

### CLINICAL UPDATES IN HEMATOLOGIC MALIGNANCIES AND RELATED SUPPORTIVE CARE

#### Program Agenda

Day 1: February 4, 2023 cont'd

<b>Myeloma</b> <b>Program Chair: Jens Hillengass, MD</b>	
2:40 pm – 2:45 pm	<b>Case Presentation of a Multiple Myeloma Patient</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
2:45 pm – 3:10 pm	<b>Upfront treatment in Multiple Myeloma</b> <i>Dr. Hamza Hassan</i> <ol style="list-style-type: none"><li>Examine induction therapy choices for transplant eligible and transplant in-eligible patients.</li><li>Discuss autologous transplant in myeloma.</li><li>Evaluate maintenance treatment options in multiple myeloma.</li></ol>
3:15 pm – 3:40 pm	<b>Updates in the Treatment of Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphomas</b> <i>Dr. Ariel Grajales-Cruz</i> <ol style="list-style-type: none"><li>Discuss the new treatments for maintenance of Waldenstrom's Macroglobulinemia.</li><li>Discuss the emerging new treatment for Waldenstrom's Macroglobulinemia including radiotherapy.</li></ol>
3:45 pm – 4:10 pm	<b>Treatment of Relapsed/Refractory Multiple Myeloma patients</b> <i>Dr. Jens Hillengass</i> <ol style="list-style-type: none"><li>State current treatment options in relapsed/refractory multiple myeloma.</li><li>Discuss considerations about sequencing of treatment.</li><li>Describe novel treatment agents on the horizon (Bi-specific antibodies and other cellular therapies).</li></ol>
4:15 pm – 4:45 pm	<b>Interactive Round table</b>
4:45 pm – 5:00 pm	<b>Closing Remarks</b>

**ROSWELL PARK COMPREHENSIVE CANCER CENTER**  
**CLINICAL UPDATES IN HEMATOLOGIC MALIGNANCIES**  
**AND RELATED SUPPORTIVE CARE**

**Program Agenda**  
**Day 2: February 5, 2023**

8:00am–8:10am	<b>Greetings and Introduction</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
<b>Leukemia/Myelodysplastic Disorders</b> <b>Program Chair: Eunice Wang, MD</b>	
8:10am-8:15am	<b>MDS Case Presentation</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
8:15am-8:40am	<b>New therapy for Myelodysplasia</b> <i>Dr. Elizabeth Griffiths</i> a. Explain how to manage low risk MDS. b. Discuss how to manage high risk MDS: novel agent. c. Discuss clonal hematopoiesis and gene profiling of MDS.
8:45am–9:10am	<b>Acute Leukemia: Novel agents</b> <i>Dr. Eunice Wang</i> a. Acute Myeloid Leukemia (AML): Review new options for unfit and older patients. b. Acute Myeloid Leukemia (AML): Discuss targeting mutated AML and leukemia stem cells. c. Discuss immunotherapy for AML, ALL, etc.
9:15am–9:40am	<b>Updates to CML and MPN</b> <i>Dr. James Thompson</i> a. Indicate which patients should receive TKI discontinuation. b. Describe how to treat TKI-failure in CML. c. Discuss MPN- Jak inhibitors and more.
9:45am–10:15am	<b>Interactive Round table</b>
10:15am–10:30am	BREAK
<b>Hodgkin Lymphoma:</b> <b>Program Chair: Francisco J. Hernandez-Ilizaliturri, MD</b>	
10:30am–10:55am	<b>Clinical Practice changes in Hodgkin’s lymphoma</b> <i>Dr. Francisco Hernandez-Ilizaliturri</i> a. Discuss the role of drug conjugates in the front-line setting for HL patients. b. Summarize the evolving changes in the management of relapsed HL, i.e., What is the best second line therapy? c. Discuss recent clinical studies evaluating the activity of checkpoint inhibitors in lymphoid malignancies.
11:00am–11:25am	<b>Behavioral changes and stress reduction strategies in young patients with HL</b> <i>Dr. David S. Kroll</i> a. How to deal with family dynamics in young patients with lymphoid malignancies. b. How The Adolescent and Young Adult (AYA) Lymphoma Programs impact the outcomes of patients with HL. c. How to recognize and treat anxiety and depression in young patients undergoing therapy for HL.

**CLINICAL UPDATES IN HEMATOLOGIC MALIGNANCIES  
AND RELATED SUPPORTIVE CARE**

**Program Agenda**

**Day 2: February 5, 2023 cont'd**

11:30pm–12:30pm	<b>PLENARY LUNCHEON</b> <b>Epigenetic clock in hematological malignancies</b> <i>Dr. Joyce Ohm</i>
12:35pm-12:40pm	<b>T-cell Lymphoma Case Presentation</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
12:40pm–1:05pm	<b>Medical Updates in systemic T-cell lymphoma</b> <i>Dr. Grant Schofield</i> a. Recognize changes in the molecular characterization of T-cell lymphoma and how this impacts clinical prognosis and treatment. b. Review practice changes in the management of T-cell lymphomas. c. What are the novel agents ready for clinical use in the management of T-cell lymphoma?
1:05pm–1:35pm	<b>Interactive Round Table</b>
<b>Low grade Lymphomas:</b> <b>Program Chair: Francisco J. Hernandez-Ilizaliturri, MD</b>	
1:35pm–1:40pm	<b>CLL Case Presentation</b> <i>Dr. Francisco J. Hernandez-Ilizaliturri</i>
1:40pm–2:05pm	<b>Updates in the Management of Chronic Lymphocytic Leukemia</b> <i>Dr. Matthew Cortese</i> a. Evaluate therapeutic approaches for CLL patients in the era of novel targeted agents. b. Appraise how the use of novel monoclonal antibodies targeting CD20 or other receptors will change the treatment paradigm of CLL patients, and patients with Low-Grade Lymphoma.
2:10pm–2:35pm	<b>Updates in the Management of Follicular Lymphoma</b> <i>Dr. Dorothy Pan</i> a. Evaluate therapeutic approaches for FL patients in the era of novel targeted agents. b. How to sequence treatment options for patients with FL. c. Appraise how the use of novel monoclonal antibodies targeting CD20 or other receptors will change the treatment paradigm of FL. d. What is the role of CAR-T CD19 therapy in relapsed/refractory FL?
2:40pm–3:05 pm	<b>Relapsed Chronic Lymphocytic Leukemia</b> <i>Dr. Sikandar Ailawadhi</i> a. Evaluate therapeutic approaches in relapsed/refractory CLL patients b. Appraise how the use of novel monoclonal antibodies targeting CD20 or other receptors will change the treatment paradigm of CLL patients with relapsed / refractory disease
3:10pm–3:40pm	<b>Interactive Round table</b>
3:45pm–4:00pm	<b>Closing remarks and adjournment</b>